

Schloß Schönbrunn, Wien Apothekertrakt und Orangerie

The search for biomarkers to predict response to immunotherapies in NSCLC patients

Gerwin Heller, PhD, Medical University of Vienna, Comprehensive Cancer Center













DISCLOSURE

Relevant financial relationship:

Research fund by BMS (CA209-894)







CONTENT

- Background
- Mutation burden and response to immunotherapies
- Gene/pathway alterations associated with response to immunotherapies
- Epigenetics DNA methylation
- Link between epigenetics and immunotherapies

PRINCIPLE OF ANTI-TUMOR IMMUNITY





© HIMSS Europe GmbH

23. – 24. MAI 2017 EHEALTH SUMMIT AUSTRIA

IMMUNOTHERAPIES ARE ...

- ... revolutionizing anti-cancer therapy
- ... active in multiple tumor types
- ... characterized by durable clinical benefit in a subset of patients

20 - 30%


Urgent need for predictive biomarkers

- PD-L1 expression (tumor cells / immune cells)
- Mutation burden / neoantigen
 expression
- Individual genes / pathways
- Epigenetic markers



MUTATION BURDEN - PREDICTIVE MARKER OF RESPONSE TO IMMUNOTHERAPIES?

23. – 24. MAI 2017 EHEALTH SUMMIT AUSTRIA



MUTATION BURDEN (MB) IN VARIOUS HUMAN TUMOR ENTITIES

© HIMSS Europe GmbH


23. – 24. MAI 2017

EHEALTH SUMMIT AUSTRIA

DETECTION OF MB: WHOLE EXOME SEQUENCING



PEMBROLIZUMAB - MISMATCH-REPAIR DEFICIENT TUMORS



High number of somatic mutations correlates with response to treatment


Le et al., 2015

23. - 24. MAI 2017

EHEALTH SUMMIT AUSTRIA

PEMBROLIZUMAB - NSCLC

IPILIMUMAB - MELANOMA




Rizvi et al., 2015

Snyder et al., 2014

High number of somatic mutations correlates with response to treatment Feasible biomarker in clinical routine??

EHEALTH SUMMIT AUSTRIA

WHOLE EXOME SEQUENCING VS TARGETED SEQUENCING



Highly comparable data between WES and Illumina TruSight Tumor 170 panel


EHEALTH SUMMIT AUSTRIA

DNA METHYLATION - PREDICTIVE MARKER OF RESPONSE TO IMMUNOTHERAPIES?

12

DNA METHYLATION


- Covalent addition of -CH₃ to carbon
 5 of cytosine within CpG dinucleotide
- Reaction catalyzed by DNA methyltransferases (DNMT)
- Co-factor: S-adenosyl-L-methionine (SAM)
- Reversible process



23. – 24. MAI 2017

CPG ISLANDS

- CpG-rich genomic regions of 0.5-4 kb in length
- Located in promoter region of ~ 60% of mammalian genes
- Usually unmethylated (exceptions: e.g. x-linked, imprinted genes)
- Tissue specific e.g. Cancer Testis Antigens




Nepomuceno et al., 2013




CANCER TESTIS ANTIGENS

- Large family of testis/placenta specific proteins
- Silenced by methylation in differentiated somatic cells
- Re-expressed various malignancies
- Recognized as non-self structures
- Induce immune response



REDUCED CTA METHYLATION IN LUSC

- TCGA data
- Lung squamous cell carcinomas
- 372 primary TUs
- 43 matching NLs
- Infinium HumanMethylation450 BeadChip




23. – 24. MAI 2017 EHEALTH SUMMIT AUSTRIA

CTA METHYLATION VS. EXPRESSION IN LUSC


MAGEA10

comparison to: expression



EHEALTH SUMMIT AUSTRIA

IS REDUCED CTA METHYLATION / INCREASED CTA EXPRESSION A PREDICTIVE MARKER?





THANK YOU VERY MUCH FOR YOUR ATTENTION!!

19

© HIMSS Europe GmbH



23. – 24. MAI 2017 EHEALTH SUMMIT AUSTRIA